Join our daily newsletter At The Bell to receive exclusive market insights
- Pregnancy technology company HeraMED (HMD) has signed a letter of intent (LOI) with virtual care provider eCare21
- This LOI will see HeraMED’s HeraCARE platform, which includes its in-home foetal and maternal heart rate monitor HeraBEAT, be integrated into the eCare21 platform
- This partnership is expected to simplify the deployment of virtual care for both the mother and her baby, especially during the COVID-19 pandemic
- This solution is expected to be available by the end of 2020
- HeraMED is steady on the market and shares are currently trading for 17 cents each
Pregnancy technology company HeraMED (HMD) has signed a letter of intent (LOI) with virtual care provider eCare21.
eCare21 is a U.S.-based virtual care platform that combines telehealth and remote patient monitoring to give patients access to remote care wherever they are.
It has a large and established customer base of healthcare providers, primarily focusing on patients with chronic conditions.
“We are confident that the eCare21 platform, combined with HeraMED’s unique and proprietary pregnancy monitoring solutions will create one of the best connected health solutions on the market,” eCare21 Founder and CEO Vadim Cherdak said.
This LOI will see HeraMED’s HeraCARE platform, which includes its in-home foetal and maternal heart rate monitor HeraBEAT, be integrated into the eCare21 platform.
This partnership is expected to simplify the deployment of virtual care for both the mother and her baby and comes at a crucial time when COVID-19 has enabled companies to fast-track the deployment of their virtual solutions.
This solution is expected to be available by the end of 2020.
“We are delighted to be partnering with such a credible and well-established virtual care operator as eCare21,” HeraMED CEO and Co-Founder David Groberman said.
“The integration of the HeraCARE platform into the eCare21 platform is expected to result in a rapid take up of HeraCARE across the healthcare providers,” he added.
HeraMED is steady on the market and shares are trading for 17 cents each at 1:09 pm AEST.
